RGEN Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 3.45% compared to Repligen's net margin of --. Repligen's return on equity of -1.16% beat Perspective Therapeutics's return on equity of --.

Repligen has a consensus price target of $183.13, signalling upside risk potential of 43.23%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 494.75%. Given that Perspective Therapeutics has higher upside potential than Repligen, analysts believe Perspective Therapeutics is more attractive than Repligen.

Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than Perspective Therapeutics quarterly revenues of --. Repligen's net income of $5.8M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Repligen's price-to-earnings ratio is 633.44x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 11.06x versus 15.67x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical has a net margin of 3.45% compared to Repligen's net margin of -3.78%. Repligen's return on equity of -1.16% beat ICU Medical's return on equity of -5.75%.

Repligen has a consensus price target of $183.13, signalling upside risk potential of 43.23%. On the other hand ICU Medical has an analysts' consensus of $186.40 which suggests that it could grow by 30.47%. Given that Repligen has higher upside potential than ICU Medical, analysts believe Repligen is more attractive than ICU Medical.

Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.976%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are smaller than ICU Medical quarterly revenues of $629.8M. Repligen's net income of $5.8M is higher than ICU Medical's net income of -$23.8M. Notably, Repligen's price-to-earnings ratio is 633.44x while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 11.06x versus 1.46x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

908 Devices has a net margin of 3.45% compared to Repligen's net margin of -103.33%. Repligen's return on equity of -1.16% beat 908 Devices's return on equity of -49.84%.

Repligen has a consensus price target of $183.13, signalling upside risk potential of 43.23%. On the other hand 908 Devices has an analysts' consensus of $5.50 which suggests that it could fall by -5.01%. Given that Repligen has higher upside potential than 908 Devices, analysts believe Repligen is more attractive than 908 Devices.

Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison 908 Devices has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. 908 Devices pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than 908 Devices quarterly revenues of $18.8M. Repligen's net income of $5.8M is higher than 908 Devices's net income of -$19.4M. Notably, Repligen's price-to-earnings ratio is 633.44x while 908 Devices's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 11.06x versus 3.31x for 908 Devices. Usually stocks with elevated PS ratios are considered overvalued.

UFP Technologies has a net margin of 3.45% compared to Repligen's net margin of 11.6%. Repligen's return on equity of -1.16% beat UFP Technologies's return on equity of 19.38%.

Repligen has a consensus price target of $183.13, signalling upside risk potential of 43.23%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 32.96%. Given that Repligen has higher upside potential than UFP Technologies, analysts believe Repligen is more attractive than UFP Technologies.

Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.100, suggesting its more volatile than the S&P 500 by 9.979%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than UFP Technologies quarterly revenues of $148.1M. Repligen's net income of $5.8M is lower than UFP Technologies's net income of $17.2M. Notably, Repligen's price-to-earnings ratio is 633.44x while UFP Technologies's PE ratio is 28.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 11.06x versus 3.33x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.